Skip to content

IPF Evaluation: Discussing the way forward

A major outcome of the British Pharmacological Society’s ‘Focus on Pharmacology’ project has been a 2016 review of the Integrative Pharmacology Fund (IPF), a shared venture with AstraZeneca, GlaxoSmithKline, Pfizer, public funders and the Society to help support in vivo knowledge and skills. The impact of the £22m fund over its 12-year lifetime was evaluated and recommendations made for in vivo education, research and training. Drawing upon expertise from across the in vivo community, the Society and The Physiological Society co-hosted a workshop in November 2017 to discuss how these recommendations might be implemented. Future challenges arising from a changing scientific landscape were discussed as well as how best to nurture networks of good practice. Going forward, we will condense the outputs of these discussions and produce a report that will inform the necessary next steps for the in vivo community to ensure a sustainable and well-rounded future in vivo landscape.

Latest news & activity

Prizes and awards

The International Union of Basic & Clinical Pharmacology (IUPHAR) have announced that Professor Michael Spedding is to receive its Lifetime…

Award

The British Pharmacological Society is delighted to announce the recipients of its 2026 PhD Funding, including the four inaugural winners of the Sir…

Press releases

 

The British Pharmacological Society’s recent position statement on medicines in pregnancy and breastfeeding has received strong national media…